Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Preclinical study of adenoviral p53 gene therapy for esophageal cancer
Autore:
Shimada, H; Shimizu, T; Ochiai, T; Liu, TL; Sashiyama, H; Nakamura, A; Matsubara, H; Gunji, Y; Kobayashi, S; Tagawa, M; Sakiyama, S; Hiwasa, T;
Indirizzi:
Chiba Univ, Grad Sch Med, Acad Dept Surg, Chuo Ku, Chiba 2608670, Japan Chiba Univ Chiba Japan 2608670 Dept Surg, Chuo Ku, Chiba 2608670, Japan Aventis Pharma Ltd, RPR Gencell Asia Pacific Inc, Tokyo, Japan Aventis Pharma Ltd Tokyo Japan R Gencell Asia Pacific Inc, Tokyo, Japan Chiba Canc Ctr, Res Inst, Chiba, Japan Chiba Canc Ctr Chiba JapanChiba Canc Ctr, Res Inst, Chiba, Japan Chiba Univ, Sch Med, Dept Biochem 1, Chiba 2608670, Japan Chiba Univ Chiba Japan 2608670 Med, Dept Biochem 1, Chiba 2608670, Japan
Titolo Testata:
SURGERY TODAY
fascicolo: 7, volume: 31, anno: 2001,
pagine: 597 - 604
SICI:
0941-1291(2001)31:7<597:PSOAPG>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
SQUAMOUS-CELL CARCINOMA; HUMAN COLON-CANCER; IN-VIVO; LUNG-CANCER; CHEMOTHERAPEUTIC-AGENTS; MEDIATED TRANSFER; EXPRESSION; MUTATION; PROTEIN; CHEMOSENSITIVITY;
Keywords:
p53; gene therapy; esophageal cancer; p21;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Shimada, H Chiba Univ, Grad Sch Med, Acad Dept Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan Chiba Univ 1-8-1 Inohana Chiba Japan 2608670 ba 2608670, Japan
Citazione:
H. Shimada et al., "Preclinical study of adenoviral p53 gene therapy for esophageal cancer", SURG TODAY, 31(7), 2001, pp. 597-604

Abstract

An alteration of the p53 gene function is a major factor in the development of esophageal cancer. Recently, p53 gene therapy has been applied for clinical studies in lung cancer and head and neck cancer. However, no preclinical studies have yet demonstrated an anticancer effect of adenoviral-mediated wild-type p53 gene therapy on esophageal cancer. We herein evaluated theeffect of p53 adenoviral gene therapy on human esophageal squamous cell carcinoma to test the ability of clinical application. A normal esophageal epithelial cell line (EN53F) and two human esophageal cancer cell lines (ECGI-10 and T.Tn) with a p53 alteration were used. The transduction efficiency,p53 protein expression, p21 protein expression, the induction of apoptosis, and growth suppression were assessed by using the recombinant adenoviral vector AdSCMV-p53. The transduction efficiency was 60%-80% at 100 plaque-forming units (PFU)/cell and 80%-100% at 300PFU/cell. A significant growth suppression following an Ad5CMV-p53 infection was observed in both cancer cell lines. A Western blot analysis confirmed the presence of both exogenous p53 protein expression and p21 protein induction. Apoptotic cell death was observed with TUNEL staining. T.Tn xenografts in nude mice transduced with Ad5CMV-p53 demonstrated significant growth suppression. These data suggest that Ad5CMV-p53 may thus be a potentially effective therapeutic agent for locally advanced esophageal cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 14:58:19